3 Potential Mid-Cap Biotech Buyout Targets In 2026

The biotech sector began December with notable weakness, as both IBB and XBI ETFs declined over two percent during trading on Monday.  The sector has bounced back since. However, small biotech stocks have been on a huge run since mid-September, due primarily to a notable uptick in M&A activity across the industry. Numerous small and midcap biotech/biopharma stocks have been purchased for significant buyout premiums in recent months.

Seeking Alpha • Dec 3, 2025

Inside the Recent Strength in Biotech ETFs

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.

Zacks Investment Research • Nov 21, 2025

iShares Biotechnology ETF: The M&A Wave Behind The Suddenly Booming Biotech Sector

The biotech sector, represented by the iShares Biotechnology ETF, has experienced a notable rally in recent months. The key driver of the 40% over the past six months has been a notable uptick in M&A volume, with another major buyout last week. Even with the huge recent rise in the biotech sector, it still trades below its level of four years ago and could go still higher if M&A volume remains elevated.

Seeking Alpha • Nov 17, 2025

If M&A continues at this pace you want to be long Biotech into next year, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk the uptick in biotech and pharma M&A, what it is signaling, and how to play it.

CNBC Television • Nov 14, 2025

Biotech is back and a constructive place to put money to work, says Piper Sandler's Craig Johnson

Craig Johnson, Piper Sandler chief market technician, joins 'The Exchange' to discuss the market technicals, if its a real market rotation and much more.

CNBC Television • Nov 11, 2025

'Fast Money' traders talk how to play biopharma space

The 'Fast Money' traders talk how to play biopharma space.

CNBC Television • Nov 11, 2025

Investing In Health Stocks - How Policy Clarity Is Opening Doors

The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.

Seeking Alpha • Nov 11, 2025

Why the Tide in Biotech May Finally Be Turning and What iShares Biotechnology ETF (IBB) Signals

Acquired 77,000 shares, valued at $11.1 million Transaction represents 8.7% of 13F reportable AUM Post-trade position: 77,000 shares valued at $11.1 million IBB is now the fund's 2nd-largest holding, accounting for 8.7% of AUM

The Motley Fool • Nov 3, 2025

Biotechnology Sector Update: Stocks and Investments to Watch

While many investors focus on semiconductors and AI or the growth sector, one of my Economic Modern Family members has been busy. The Biotech Sector ETF (NASDAQ: IBB), has made new multi-year highs.

See It Market • Oct 31, 2025

Biotech ETFs Hovering Around a 52-Week: Here's Why

Biotech-based exchange-traded fund (ETF) iShares Biotechnology ETF IBB has rallied 26.1% over the past six months (as of Oct. 27, 2025), outperforming SPDR S&P 500 ETF Trust SPY (up 24.4%). Year to date, IBB has risen 18.2% versus SPY's 17.2% gain.

Zacks Investment Research • Oct 30, 2025